Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUNX1 | Q01196 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 9/20 | 0.40 |
| ▸ | DRD2 | P14416 | 6/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19228806 | 0.85 | RUNX1 (0.55) | RUNX1ACHEDRD3DRD2 | |
| SCHEMBL19228808 | 0.85 | RUNX1 (0.57) | RUNX1ACHEDRD3DRD2CHEK2 | |
| SCHEMBL19228814 | 0.84 | ACHE (0.56) | RUNX1ACHEDRD3DRD2TBK1 | |
| SCHEMBL19228818 | 0.84 | KCNA5 (0.54) | RUNX1DRD3DRD2KCNA5 | |
| SCHEMBL19228815 | 0.83 | RUNX1 (0.55) | RUNX1ACHEDRD3DRD2 | |
| SCHEMBL19228805 | 0.83 | RUNX1 (0.68) | RUNX1ACHEDRD3DRD2DHODH | |
| SCHEMBL19228807 | 0.79 | RUNX1 (0.52) | RUNX1ACHE | |
| SCHEMBL17525978 | 0.79 | RUNX1 (0.63) | RUNX1DRD3DRD2KCNA5 | |
| SCHEMBL19228816 | 0.74 | CBFB (0.45) | RUNX1ACHE | |
| SCHEMBL26051103 | 0.70 | CBFB (0.41) | RUNX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | RUNX1 1/4885ACHE 2581/4885DRD3 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.